Teva Canada Limited v. Pfizer Canada Inc., 2019 FCA 15
| Court | Federal Court of Appeal (Canada) |
| Case Date | January 25, 2019 |
| Jurisdiction | Canada (Federal) |
| Citations | 2019 FCA 15 |
-
- This document is available in original version only for vLex customers
View this document and try vLex for 7 days - TRY VLEX
- This document is available in original version only for vLex customers
22 practice notes
-
Angelcare Canada Inc. v. Munchkin, Inc., 2022 FC 507
...not all the chemical’s properties will inform its inventive concept (Bristol-Myers at para. 74; Teva Canada Limited v. Pfizer Canada Inc., 2019 FCA 15 at para. 34). [77] In sum, a single inventive concept must flow through a patent, but each claim’s specific inventive concept may be differe......
-
Eli Lilly Canada Inc. v. Apotex Inc., 2020 FC 814
...cannot be disregarded when considering the second point in the inventiveness analysis, and cite Teva Canada Limted v Pfizer Canada Inc, 2019 FCA 15 at para 35 and Apotex Inc v Pfizer Canada Inc, 2019 FCA 16 at para 39. [252] Lilly argue that, under the obviousness analysis, the subject-matt......
-
Greenblue Urban North America Inc. v. Deeproot Green Infrastructure, LLC, 2023 FCA 184
...Energy Services Ltd., 2019 FCA 96, 164 C.P.R. (4th) 191 at para. 29 [Packers] (on obviousness); Teva Canada Limited v. Pfizer Canada Inc., 2019 FCA 15, 163 CPR (4th) 265 at para. 23 (on obviousness); Seedlings Life Science Ventures, L.L.C. v. Pfizer Canada U.L.C., 2021 FCA 154, 339 A.C.W.S.......
-
AbbVie Corporation v. Jamp Pharma Corporation, 2023 FC 1520
...factor amongst many that may assist in the obviousness inquiry: Bristol-Myers Squibb at para 38; Teva Canada Limited v Pfizer Canada Inc, 2019 FCA 15 at para (2) Commercial Success and Meritorious Awards [184] Commercial success and meritorious awards may be a relevant consideration under t......
Request a trial to view additional results
11 cases
-
Angelcare Canada Inc. v. Munchkin, Inc., 2022 FC 507
...not all the chemical’s properties will inform its inventive concept (Bristol-Myers at para. 74; Teva Canada Limited v. Pfizer Canada Inc., 2019 FCA 15 at para. 34). [77] In sum, a single inventive concept must flow through a patent, but each claim’s specific inventive concept may be differe......
-
Eli Lilly Canada Inc. v. Apotex Inc., 2020 FC 814
...cannot be disregarded when considering the second point in the inventiveness analysis, and cite Teva Canada Limted v Pfizer Canada Inc, 2019 FCA 15 at para 35 and Apotex Inc v Pfizer Canada Inc, 2019 FCA 16 at para 39. [252] Lilly argue that, under the obviousness analysis, the subject-matt......
-
Greenblue Urban North America Inc. v. Deeproot Green Infrastructure, LLC, 2023 FCA 184
...Energy Services Ltd., 2019 FCA 96, 164 C.P.R. (4th) 191 at para. 29 [Packers] (on obviousness); Teva Canada Limited v. Pfizer Canada Inc., 2019 FCA 15, 163 CPR (4th) 265 at para. 23 (on obviousness); Seedlings Life Science Ventures, L.L.C. v. Pfizer Canada U.L.C., 2021 FCA 154, 339 A.C.W.S.......
-
AbbVie Corporation v. Jamp Pharma Corporation, 2023 FC 1520
...factor amongst many that may assist in the obviousness inquiry: Bristol-Myers Squibb at para 38; Teva Canada Limited v Pfizer Canada Inc, 2019 FCA 15 at para (2) Commercial Success and Meritorious Awards [184] Commercial success and meritorious awards may be a relevant consideration under t......
Request a trial to view additional results
11 firm's commentaries
-
Form I: Crystal Form Patents In The Federal Court Of Canada ' A Review Of Case Law On Claims Construction And Selection Patents
...29 Sitagliptin, supra, para. 95. 30 Pfizer Canada Inc. v. Teva Canada Limited, 2017 FC 777 ("Teva-Venlafaxine""), paras. 288-293, aff'd 2019 FCA 15. 31 Teva-Venlafaxine, supra, paras. The content of this article is intended to provide a general guide to the subject matter. Specialist advice......
-
Form II: Anticipation And Obviousness Of Crystal Form Patents In The Federal Court Of Canada
...FC 1142 paras. 116-121 ("Efavirenz"). 7. Efavirenz supra at paras. 119-120. 8. Pfizer Canada Inc. v. Teva Canada Ltd., 2017 FC 777 aff'd 2019 FCA 15 ("Desvenlafaxine-Teva") and Pfizer Canada Inc. v. Apotex Inc., 2017 FC 774 aff'd 2019 FCA 16 ("Desvenlafaxine-Apotex"), collectively, 9. FC De......
-
Orders of prohibition relating to polymorphic form patent for PRISTIQ upheld on appeal
...Court of Appeal (FCA) dismissed both Apotex’s and Teva’s appeals: Teva v Pfizer, 2019 FCA 15; Apotex v Pfizer, 2019 FCA The 668 Patent relates to a novel crystal form of a particular salt of ODV: Form I ODV succinate. Obviousness was the only issue in the Teva appeal. Obviousness and antici......
-
FCA Confirms Entirety Of Inventors' Conduct Is Relevant In Obviousness Analysis And Upholds Inventiveness Of Crystal Form Patent
...it. *Special thanks to Jamie Parker, an articling student, for his help on this post. Link: Teva Canada Ltd. v. Pfizer Canada Inc. et al., 2019 FCA 15; Apotex Inc. v. Pfizer Canada Inc. et al., 2019 FCA About Norton Rose Fulbright Canada LLP Norton Rose Fulbright is a global law firm. We pr......
Request a trial to view additional results